MagicRNA announced that it has received $2,900,000 in funding led by Shenzhen Hongtao Fund Management Co., Ltd. on December 30, 2022. The transaction included participation from Goldport Capital, Shenzhen Credit Guarantee Group Co., Ltd, Hinova Pharmaceuticals Inc., and NLPE.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
28.32 CNY | -1.12% | +6.87% | -45.61% |
26/04 | Hinova Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
08/04 | China Stocks Fall Ahead of March Economic Data Release | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-45.61% | 386M | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- 688302 Stock
- News Hinova Pharmaceuticals Inc.
- MagicRNA announced that it has received $2.900000 million in funding from Goldport Capital, Shenzhen Credit Guarantee Group Co., Ltd, Hinova Pharmaceuticals Inc., NLPE, Shenzhen Hongtao Fund Management Co., Ltd. and other investors.